Peptide-VLP Vaccines

肽-VLP疫苗

基本信息

批准号：
10362597
负责人：
Bryce C Chackerian
金额：
$ 21.75万
依托单位：
HENRY M. JACKSON FDN FOR THE ADV MIL/MED
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-03-26 至 2024-02-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10362597
关键词：
Affect Antibiotic Resistance Antibodies Antibody Response Antigens Bacteriophages Binding Carrier Proteins Ceftriaxone Cervical Cervicitis Chemicals Clinical Collaborations Complement Core Facility Country Ectopic Pregnancy Engineering Epitopes Fright Goals Gonorrhea Human Human Papillomavirus Immune response Immunologics Incidence Infection Iron Licensure Measures Mediating Membrane Membrane Proteins Modeling Mucosal Immune Responses Mucous Membrane Mus Neisseria gonorrhoeae Pathogenesis Pathway interactions Pelvic Inflammatory Disease Peptides Phase Play Reproductive Tract Infections Research Resources Role Serum Services Sexually Transmitted Diseases Specificity Surface Techniques Technology Testing Transferrin Transferrin-Binding Protein A United States Urethritis VDAC1 gene Vaccine Production Vaccines Variant Virus-like particle azithromycin resistance bactericide base chronic pelvic pain efficacy testing efflux pump flexibility genital infection gonorrhea vaccine human pathogen immunogenic immunogenicity mouse model novel vaccines prophylactic recombinant virus reproductive tract resistant strain tubal infertility vaccine candidate vaccine development vaccine immunogenicity vaccine platform vaccine-induced antibodies

项目摘要

PROJECT SUMMARY Neisseria gonorrhoeae (Ng) is an obligate human pathogen that causes gonorrhea, one of the most common sexually transmitted infections. The incidence of Ng infection in the United States is rising, and the emergence of multi-antibiotic resistant strains have led to fears that treatment options for gonorrhea are decreasing. The overall goal of the Gonorrhea Vaccine Cooperative Research Center (GV CRC) is to identify promising new vaccine candidates for Ng. In this project, our central hypothesis is that an effective gonorrhea vaccine can be developed by engineering highly immunogenic vaccines that specifically target critical surface-exposed Ng epitopes. To do this, we will utilize a flexible and highly immunogenic vaccine platform technology that is based of bacteriophage virus-like particles (VLPs). In Aim 1, we will engineer VLP-based vaccines that target surface- exposed epitopes of four Ng antigens that are potential vaccine targets. In Aim 2, we will measure the immunogenicity of candidate vaccines and assess the bactericidal and opsonophagocytic activity of induced antibodies. In Aim 3, we will test the efficacy of the most promising VLP vaccines in challenge studies using mouse genital tract infection models. These studies will benefit from extensive collaborations with the GV CRC Core facilities and complement the vaccine development efforts of the other Projects.

项目摘要 Neisseria Gonorrhoeae（NG）是一种强制性的人类病原体，导致淋病，最常见的病原体之一性传播感染。美国NG感染的发生率正在上升，出现了多抗抗生素抗性菌株的菌株使人们担心淋病的治疗选择正在减少。这淋病疫苗合作研究中心（GV CRC）的总体目标是确定有希望的新 NG的疫苗候选物。在这个项目中，我们的中心假设是有效的淋病疫苗可以是通过工程高度免疫原性疫苗开发，该疫苗专门针对临界表面暴露的NG 表位。为此，我们将利用一种基于的灵活且高度免疫原性的疫苗平台技术噬菌体病毒样颗粒（VLP）。在AIM 1中，我们将设计基于VLP的疫苗，以靶向表面潜在的疫苗靶标的四个NG抗原的暴露表位。在AIM 2中，我们将衡量候选疫苗的免疫原性，并评估诱导的杀菌性和眼吞噬活性抗体。在AIM 3中，我们将在挑战研究中测试最有希望的VLP疫苗的功效小鼠生殖道感染模型。这些研究将受益于与GV CRC的广泛合作核心设施并补充其他项目的疫苗开发工作。